Abstract 626P
Background
Roginolisib, a highly selective modulator of PI3Kδ, reinvigorates antitumor immunity in patients with metastatic uveal melanoma (mUM).
Methods
Roginolisib was investigated in a First-in-human (FIH) dose escalation (Part A) and in a dose expansion (Part B) study at the biologically effective dose (BED) of 80 mg QD in mUM pts. Primary objective: Safety. Secondary objectives: PK; PD (e.g., CD63 expression on basophils, changes in immune cell subsets in peripheral blood); radiographic responses (RECIST v1.1); PFS and OS. Exploratory: changes in circulating immune cells by mass cytometry; response assessments by radiomics and blood-based proteins.
Results
At the BED of 80 mg QD, no treatment-related dose modifications or dose-limiting toxicity (DLT) were seen. Twenty-nine patients had mUM (Part A: 9 pts; Part B: 20 pts). Mean time on treatment: 10.9 mo (range: 1.5-42.6 mo). ORR (RECIST v1.1): PR: 1/29 (3%); SD: 20/29 (69%). Median OS for Part A: 20.8 mo; Part B: ongoing; Part A+B: ongoing. Roginolisib decreased circulating regulatory T cells and concomitantly increased CD8T and NK cells. This pattern of immune cell balances was accompanied by a decrease in soluble CTLA4 and an increase of IL15. Volumetric reduction in spleen was observed in most of the mUM patients. Based on RECIST v1.1, two distinct groups were recognized at Week 16 (3.8 mo): pts with SD (median OS: 20 mo; 13/29; 45%) and pts with PD (median OS: 10 mo). Pts with SD had slow volumetric increases by radiomic evaluation of all tumour lesions. Both patient groups had similar tumour genetic backgrounds. The main differences between SD and PD pts at Week 16 were increased activated CD8T cells and IFNγ signaling for SD pts. Furthermore, PI3K-associated signaling molecules and immune-exhaustion markers were significantly higher at baseline in the SD compared to PD pts and decreased only in the SD pts.
Conclusions
Uninterrupted administration of roginolisib in mUM pts with advanced malignancies is well tolerated, exhibits immuno-modulatory effects, and in a subset of pts with mUM, shows immune cell activation with associated survival benefit.
Clinical trial identification
NCT04328844.
Editorial acknowledgement
The authors thank the patients and their families. Also, we thank all study personal at the clinical investigation centers, the Fortrea Drug Development team and the statistical support from Veramed.
Legal entity responsible for the study
iOnctura SA.
Funding
iOnctura SA.
Disclosure
A.M. Di Giacomo: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, MSD, Pierre Fabre, Novartis, Immunocore; Financial Interests, Personal, Invited Speaker: Sanofi. M. Simonelli: Financial Interests, Personal, Advisory Board: Incyte, Cytovia; Financial Interests, Personal, Invited Speaker: GSK, Bristol Myers Squibb; Financial Interests, Personal, Other, Data Monitoring Committee: Sanofi. M. Lahn: Financial Interests, Personal, Officer: iOnctura SA. G. Di Conza, T. Hammett, R. Zorrilla: Financial Interests, Personal, Membership or affiliation: iOnctura. P. Kaur: Financial Interests, Institutional, Full or part-time Employment, I was employed at AstraZeneca until March 31st 2023: AstraZeneca; Financial Interests, Institutional, Full or part-time Employment, I have been employed at iOnctura since April 2023: iOnctura SA; Financial Interests, Personal, Stocks/Shares, Received shares as part of my employment up until 31 March 2023 - I have retained these shares: AstraZeneca; Non-Financial Interests, Member, Registered member as April 2023: European Hematology Association. T. Lakshmikanth: Financial Interests, Personal, Stocks/Shares, Cofounder and share holder in Cytodelics AB, Sweden with no remuneration: Cytodelics AB. M. Occhipinti: Financial Interests, Personal, Officer: Radiomics. P. Spiliopoulou: Financial Interests, Personal, Invited Speaker: Pfizer. T.R.J. Evans: Financial Interests, Institutional, Advisory Board for GI cancers and melanoma (immune checkpoint inhibitors): Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker, Invited speaker - GI cancers, melanoma, immunotherapy: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Boards - GI cancers, melanoma: Roche/Genentech; Financial Interests, Institutional, Invited Speaker, Invited speaker GI cancer, melanoma: Roche/Genentech; Financial Interests, Institutional, Advisory Board (Lenvatinib): Eisai; Financial Interests, Institutional, Invited Speaker, Speaker's fees (lenvatinib): Eisai; Financial Interests, Institutional, Advisory Board: MSD, AstraZeneca, Bayer, Bicycle Therapeutics, Clovis; Financial Interests, Institutional, Invited Speaker, Speaker's fees: MSD, AstraZeneca, Bayer; Financial Interests, Institutional, Advisory Board: Nucana; Financial Interests, Institutional, Invited Speaker, speaker's fees: Nucana; Financial Interests, Institutional, Advisory Board, advisory board; Chair of Scientific Advisory Council (HCC & MIV-818): Medivir; Financial Interests, Institutional, Invited Speaker, speaker's fees (and presentation to potential investors): Medivir; Financial Interests, Personal, Other, Support to attend international conferences: Bristol Myers Squibb, Roche/Genentech, MSD, Nucana, Bayer, Celgene, Pierre Fabre; Financial Interests, Institutional, Advisory Board for Upper GI Cancer: Ascelia; Financial Interests, Institutional, Advisory Board for Oesophageal Cancer: Seagen; Financial Interests, Institutional, Coordinating PI, Educational grant (supply of study agents) for investigator-led study and reimbursement of study costs for commercial studies: AstraZeneca; Financial Interests, Institutional, Local PI, reimbursement of study costs for commercial studies: Astellas, Bayer, Basilea, Celgene, GSK, Roche, Medivir, Starpharma, Immunocore, Novartis, Sapience Therapeutics, MiNa Therapeutics, Lilly, Bicycle Therapeutics, Sierra, CytomX, BeiGene, Pfizer, Johnson & Johnson, UCB, Codiak, Avacta, Nurix, T3P, Amgen, Moderna; Financial Interests, Institutional, Coordinating PI, reimbursement of study costs for commercial studies: Adaptimmune, Bristol Myers Squibb, Eisai, MSD, Nucana, iOnctura, Sanofi; Financial Interests, Institutional, Local PI, support for non-commercial investigator-led study: Verastem; Financial Interests, Institutional, Local PI, reimbursement for costs of commercial studies: Boehringer Ingelheim; Financial Interests, Institutional, Local PI, reimbursement of costs of commercial study: Seagen; Financial Interests, Institutional, Funding, reimbursement of study costs for commercial studies; lead investigator for infrastructure investment to NHS Research Scotland: BioNTech; Financial Interests, Institutional, Local PI, reimbursement of study sots for commercial studies: Exelixis; Non-Financial Interests, Other, Member of Scientific Advisory Panel: Pancreatic Cancer Research Fund; Non-Financial Interests, Other, Annual Meeting abstracts committee: International Liver Cancer Association; Non-Financial Interests, Institutional, Product Samples, Supply of investigational and licensed compounds for a non-commercial study for which I'm Chief Investigator: AstraZeneca; Non-Financial Interests, Member, Cancer Society Member: American Society of Clinical Oncology, America Association for Cancer Research, British Association for Cancer Research, Association of Cancer Physicians (UK), European Association for Cancer Research, International Liver Cancer Association; Other, Editor-in-Chief: British Journal of Cancer; Other, Chair of Independent Data Monitoring Committee for a phase 1 trial - honorarium payable to the employing institution: Genmab; Other, Chair and panel member, Scientific Evaluation Committee: early phase trials (Amgen, Merck, AstraZeneca); Chair and panel member, CLIP (early phase trial centres) 5-year review: Institut National du Cancer (France); Other, Panel Member, Pancreas Cancer funding committee, 2023: Fondation ARC; Other, NHS Research Scotland cancer research network national clinical lead: NHS Research Scotland. M. Maio: Financial Interests, Personal, Advisory Board: BMS, Roche, GSK, Sanofi, Alfasigma, Amgen, Sciclone, Eli Lilly, MSD, Incyte, Pierre Fabre, AstraZeneca, Pfizer, Merck Serono; Financial Interests, Personal, Stocks/Shares: Epigen, Theravance. All other authors have declared no conflicts of interest.
Resources from the same session
641P - Phase I/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors
Presenter: Ana Gil Torralvo
Session: Poster session 01
642P - Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC
Presenter: Qing Zhou
Session: Poster session 01
644P - Preliminary results of GQ1005 in metastatic HER2-low expressing breast cancer and HER2 positive gastric cancer
Presenter: Ting Deng
Session: Poster session 01
645P - Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
Presenter: Dazhi Liu
Session: Poster session 01
646P - A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Presenter: Christopher Twelves
Session: Poster session 01
Resources:
Abstract
647P - EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study
Presenter: Elisa Fontana
Session: Poster session 01
649P - Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors
Presenter: Hua Zhong
Session: Poster session 01
650P - Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 01
651P - Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors
Presenter: Jinming Yu
Session: Poster session 01